Facility Design and Engineering

The new facility, located in Lenexa, KS, will rapidly expand production of viral transport media.

How real estate can accelerate productivity as life sciences companies prioritize COVID-19 therapeutics, vaccines, and new diagnostics R&D amidst new guidelines.

Medical management services provider, Europital, has announced the opening of a new site in Oxford, United Kingdom, in response to demand from small and medium innovators within the biotech industry.

The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.

The European Medicines Agency recently approved two European Novartis sites in France and Switzerland for the commercial manufacturing of chimeric antigen receptor T-cell cell therapies.

The expansion will involve using the facilities’ existing central utilities and labs to supplement its small-scale and large-scale assets.

The expanded facility will feature two new 40-L and 300-L manufacturing vessels, a capsule filling line, and six drying tunnels that will add more than 10 million doses per annum to the site.

The investment will allow for the expansion of analytical R&D efforts and will support the company’s reference materials business.

Filling and packaging of primary containers is a crucial piece of COVID-19 vaccine production.

The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.

The new site will offer initial design and development, low-volume manufacturing, and scalable high-quality production of wearable drug delivery devices.

The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.

Manufacturers must address scale-out challenges of autologous cell therapy for commercial manufacturing.

The expansion included adding new softgel encapsulation lines at its Strathroy, Canada and Sorocaba, Brazil sites for Catalent’s Vegicaps plant-based capsule and its CosmoPod twist-off capsule technologies.

The site can now support customized product and bioprocess development and custom cell and gene therapy reagent manufacturing.

The refurbishment provides enhanced glass melting power, improved glass distribution, and the production of transparent and amber type I glass bottles to meet the increase in demand for glass vials for vaccines and life-saving medicines.

Honeywell Forge Cybersecurity Suite’s improved industrial-grade remote access and added protection and risk monitoring aids remote operations.

The updated facility is 60,000 square feet and is equipped with bioprocessing capabilities ranging from 10L to 2000L.

The company will invest $75 million into its Canton, MA, facility to expand its viral vector, gene therapy, and contract development and manufacturing capabilities.

The company will invest EUR 610 million (USD$682 million) into a new vaccine production site and research center in France.

The company is planning on adding up to 1.5 million sq. ft. of cGMP distribution space for COVID-19 shipments.

The investment will increase production lines for bulk drug substance and will add a fill/finish production line to the site.

Siemens and Exyte partner for fast-track construction of modular, automated, digitalized biopharmaceutical facilities.

The acquisition gives Novovax an annual operating capacity of more that one billion doses of COVID-19 vaccine antigen.

Automated sampling systems and integration of PAT are overcoming some of the roadblocks to increased automation of biopharmaceutical manufacturing processes.

The new facility in County Mayo includes an ISO class 7 cleanroom for the manufacturing of single-use systems.

The company will invest $180 million to construct a new 290,000-ft2 facility in Plainville, MA.

The center will be located at NJIT’s Life Sciences and Engineering center and will feature two good manufacturing practices suites that are expected to be completed and operational during the summer of 2020.

Remote, machine health monitoring services reduce the need for on-site visits.

The goal of the collaboration is to manufacture up to one billion does per year of mRNA-1273, Moderna’s vaccine against the novel coronavirus.